<DOC>
	<DOCNO>NCT00428207</DOCNO>
	<brief_summary>The purpose study determine : 1. whether difference insulin aspart insulin lispro continuous insulin pump therapy 2. whether duration insulin infusion set placement effect blood sugar control infusion set place longer 72-96 hour</brief_summary>
	<brief_title>Glycemic Stability Insulin Aspart Versus Insulin Lispro Insulin Pump Therapy</brief_title>
	<detailed_description>Insulin instability pump infusion system result unexplained hyperglycemia patient continuous subcutaneous insulin infusion ( CSII ) therapy . We note pump patient develop glycemic instability use insulin lispro , resolve change insulin aspart . Several patient use lispro report noting whitish precipitate infusion set , two case examine catheter confirm biochemically precipitate insulin . Furthermore , vitro study indicate insulin aspart resistant isoelectric precipitation insulin lispro . Although rare patient notice visible precipitate pump catheter , subset patient use lispro note blood glucose level tend rise 2 day insertion new pump infusion system . These finding mirror bench study show relative stability difference aspart lispro pump infusion system become apparent time . The endpoint examine previous randomized clinical trial compare aspart lispro direct specifically assess effect insulin type glycemic stability . In previous study , pump infusion system change every 48 hour whereas pump patient routinely replace infusion catheter every 72-96 hour ; discrepancy may account failure trial demonstrate difference stability insulin aspart lispro note clinical practice . This investigator-initiated clinical trial intend assess safety efficacy CSII insulin aspart compare insulin lispro use pump infusion catheter 96 hour .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec , insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Lispro</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<criteria>Type 1 diabetes treat CSII least 3 month . Males female , &gt; 18 year &lt; 75 year old . Hemoglobin A1c ≤ 8.0 % measurement take week 0 ( screen visit ) . Duration diabetes ≥ 12 month . Willingness perform selfblood glucose monitor several times/day . Previous insulin precipitation pump infusion catheter . Daily insulin requirement &gt; 25 % pump reservoir capacity . ( This would preclude subject use pump infusion system 3 day ) . Use insulin pump downloadable record basal bolus dos . Known suspect allergy trial product . Pregnancy , breastfeeding , intention become pregnant inadequate contraception measure . Known suspect alcohol drug abuse . Impaired renal function creatinine ≥ 1.7 mg/dl . Pronounced catheter site scar . Chronic use drug may influence glycemic control ( e.g . steroid ) . Any significant concomitant disease would interfere participation completion trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>type 1 diabetes , insulin pump therapy , glycemic stability</keyword>
</DOC>